Journal of Clinical Oncology, Vol 9, 860-864, Copyright © 1991 by American Society of Clinical Oncology
Intravenous carboplatin for recurrent malignant glioma: a phase II study
WK Yung, L Mechtler and MJ Gleason
Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston 77030.
Thirty patients with recurrent malignant glioma were treated with
intravenous (IV) carboplatin (CBDCA) every 4 weeks at a starting dose of
400 mg/m2 escalating to 450 mg/m2. All patients had documented recurrent
tumor after prior radiotherapy but had not received prior chemotherapy. Of
29 assessable patients, four (14%) responded to the treatment for 44, 51+,
72, and 91 weeks; 10 (34%) achieved stable disease (S); while 15 (52%) had
progressive disease (P). The total response (responses plus S) rate was
48%, with a median time to progression (MTP) of 26 weeks in these patients;
the MTP for all 29 patients was 11 weeks. The toxic effects were mainly
hematologic, with thrombocytopenia and granulocytopenia being mild at 400
mg/m2 and 450 mg/m2 doses. NO neurotoxicity or renal toxicity was
encountered. These results suggest that CBCDA given at 400 mg/m2 or 450
mg/m2 every 4 weeks is marginally active in patients with recurrent
malignant gliomas. Since hematologic toxicity is mild, a higher dose could
possibly be given, and may increase the response rate.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
K. Jahnke, L. L. Muldoon, C. G. Varallyay, S. J. Lewin, D. F. Kraemer, and E. A. Neuwelt
Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model
Neuro-oncol,
January 1, 2009;
11(2):
142 - 150.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Stupp, M. E. Hegi, M. J. van den Bent, W. P. Mason, M. Weller, R. O. Mirimanoff, J. G. Cairncross, and on behalf of the European Organisation for Researc
Changing paradigms--an update on the multidisciplinary management of malignant glioma.
Oncologist,
February 1, 2006;
11(2):
165 - 180.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-J. See, V. A. Levin, W.-K. A. Yung, K. R. Hess, and M. D. Groves
13-cis-Retinoic acid in the treatment of recurrent glioblastoma multiforme
Neuro-oncol,
July 1, 2004;
6(3):
253 - 258.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Fortin, J. A. Salame, A. Desjardins, and A. Benko
Technical Modification in the Intracarotid Chemotherapy and Osmotic Blood-Brain Barrier Disruption Procedure to Prevent the Relapse of Carboplatin-Induced Orbital Pseudotumor
AJNR Am. J. Neuroradiol.,
May 1, 2004;
25(5):
830 - 834.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Brandes, U. Basso, M. Reni, F. Vastola, A. Tosoni, G. Cavallo, L. Scopece, A. J. Ferreri, M. G. Panucci, S. Monfardini, et al.
First-Line Chemotherapy With Cisplatin Plus Fractionated Temozolomide in Recurrent Glioblastoma Multiforme: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia
J. Clin. Oncol.,
May 1, 2004;
22(9):
1598 - 1604.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Brandes, U. Basso, F. Vastola, A. Tosoni, L. M. Pasetto, A. Jirillo, S. Lonardi, M. K. Paris, H. Koussis, S. Monfardini, et al.
Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study
Ann. Onc.,
December 1, 2003;
14(12):
1727 - 1731.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Prados, S. C. Schold Jr., H. A. Fine, K. Jaeckle, F. Hochberg, L. Mechtler, M. R. Fetell, S. Phuphanich, L. Feun, T. J. Janus, et al.
A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma
Neuro-oncol,
April 1, 2003;
5(2):
96 - 103.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. I. Robins, S. M. Chang, M. D. Prados, W.K. A. Yung, K. Hess, D. Schiff, H. Greenberg, K. Fink, K. Nicolas, J. G. Kuhn, et al.
A phase II trial of thymidine and carboplatin for recurrent malignant glioma: A North American Brain Tumor Consortium Study
Neuro-oncol,
April 1, 2002;
4(2):
109 - 114.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. S. Agarwala and J. M. Kirkwood
Temozolomide, a Novel Alkylating Agent with Activity in the Central Nervous System, May Improve the Treatment of Advanced Metastatic Melanoma
Oncologist,
April 1, 2000;
5(2):
144 - 151.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
W.K. A. Yung, M. D. Prados, R. Yaya-Tur, S. S. Rosenfeld, M. Brada, H. S. Friedman, R. Albright, J. Olson, S. M. Chang, A. M. O'Neill, et al.
Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First Relapse
J. Clin. Oncol.,
September 1, 1999;
17(9):
2762 - 2762.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Chamberlain and P. A. Kormanik
Salvage Chemotherapy With Tamoxifen for Recurrent Anaplastic Astrocytomas
Arch Neurol,
June 1, 1999;
56(6):
703 - 708.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. A. Levin
Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: The past decade and where we are heading
Neuro-oncol,
January 1, 1999;
1(1):
69 - 80.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. C. Chamberlain, D. Barba, P. Kormanik, A. M. Berson, W. M. Saunders, and M. C. Shea
Concurrent Cisplatin Therapy and Iodine 125 Brachytherapy for Recurrent Malignant Brain Tumors
Arch Neurol,
February 1, 1995;
52(2):
162 - 167.
[Abstract]
[PDF]
|
|
|
|
